I-Mab will present updated Phase 1 study data on givastomig, a bispecific antibody targeting Claudin 18.2-positive gastric cancers, at the AACR-NCI-EORTC conference in Boston in October 2025.

I-Mab, a biotech company focused on immuno-oncology, announced participation in upcoming investor conferences and highlighted positive Phase 1b trial results for givastomig, a potential treatment for gastric cancers.

I-Mab, a biotech company, is raising $65 million through an underwritten offering of 33,333,334 American Depositary Shares at $1.95 per ADS, with proceeds intended to fund clinical development of its pipeline, particularly the givastomig drug candidate.

I-Mab reported promising Phase 1b trial results for givastomig, a bispecific antibody targeting Claudin 18.2-positive gastric cancers, demonstrating an 83% objective response rate in combination with immunochemotherapy.

I-Mab, a U.S.-based biotech company, reported positive momentum in its Phase 1b combination trial for givastomig in first-line gastric cancer, with topline data expected in 2H 2025. The company has a strong financial position with $173.4 million in cash and cash equivalents, providing a runway into 2027.